Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $134M | $155M | $164M | $175M | $198M | $132M | $109M | $145M | $233M | $491M |
| Revenue growth | — | 16.0% | 6.0% | 6.8% | 13.1% | -33.5% | -17.0% | 32.7% | 60.5% | 110.5% |
| Operating income | -$58.2M | -$53.8M | -$80.0M | -$137M | -$176M | -$199M | -$320M | -$388M | -$324M | -$62.8M |
| Operating margin | -43.6% | -34.7% | -48.7% | -78.3% | -88.8% | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| Net income | -$47.9M | -$59.7M | -$103M | -$146M | -$169M | -$180M | -$278M | -$111M | -$322M | -$25.5M |
| Net margin | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
| EPS (diluted) | -$1.29 | -$1.54 | -$2.54 | -$3.46 | -$3.56 | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.44M | $7.40M | -$25.0M | -$58.2M | -$42.7M | -$14.8M | -$186M | -$280M | -$237M | $37.8M |
| Capital expenditures | $1.43M | $887K | $727K | $195K | $6.77M | $5.10M | $191K | $668K | — | — |
| Free cash flow | -$4.87M | $6.52M | -$25.7M | -$58.4M | -$49.5M | -$19.9M | -$186M | -$281M | — | — |
| Share buybacks | $0.00 | — | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.0M | $99.4M | $103M | $62.4M | $84.8M | $166M | $61.7M | $58.2M | $58.5M | $93.0M |
| Total assets | $525M | $520M | $709M | $605M | $607M | $777M | $673M | $789M | $594M | $605M |
| Total liabilities | $218M | $227M | $391M | $384M | $396M | $475M | $630M | $588M | $535M | $490M |
| Shareholders' equity | $308M | $293M | $318M | $221M | $211M | $302M | $42.9M | $201M | $59.1M | $115M |
| Retained earnings | -$113M | -$178M | -$270M | -$416M | -$586M | -$766M | -$1.01B | -$1.13B | -$1.45B | -$1.47B |
| Shares (wtd avg diluted) | 38.3M | 38.8M | 40.4M | 42.3M | 47.5M | 59.8M | 63.8M | 74.3M | 78.9M | 89.2M |
Every figure is extracted from Travere Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.